Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer

NCT07192432 is registered in ClinicalTrials.gov with Vironexis Biotherapeutics Inc. as lead sponsor.

NCT NCT07192432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human Study of VNX-202 Gene Therapy in Patients With HER2-Positive Cancer
Lead sponsor
Vironexis Biotherapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 18, 2025
Completion date
October 31, 2033
Enrollment
27 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

her2 expressing solid tumors